Simple eye ointment

Land: Storbritannia

Språk: engelsk

Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktiv ingrediens:

Wool fat; Liquid paraffin; Yellow soft paraffin

Tilgjengelig fra:

Teva UK Ltd

INN (International Name):

Wool fat; Liquid paraffin; Yellow soft paraffin

Dosering :

100mg/1gram ; 100mg/1gram ; 800mg/1gram

Legemiddelform:

Eye ointment

Administreringsrute:

Ocular

Klasse:

No Controlled Drug Status

Resept typen:

Valid as a prescribable product

Produkt oppsummering:

BNF: 11080100; GTIN: 5020220294336

Informasjon til brukeren

•
Keep out of the sight and reach of children.
•
Do not use the ointment after the expiry date which is printed on the
carton and the crimp seal of the tube. The expiry date refers to the
last
day of that month.
•
Do not store this ointment above 25°C.
•
Once you have opened the tube it should be discarded after 28 days.
•
Do not throw away any medicines via wastewater or household waste.
Ask your pharmacist how to throw away medicines you no longer use.
These measures will help protect the environment.
WHAT SIMPLE EYE OINTMENT CONTAINS
The ingredients are yellow soft paraffin 80%w/w, liquid paraffin
10%w/w and
wool fat (lanolin) 10%w/w.
WHAT SIMPLE EYE OINTMENT LOOKS LIKE AND CONTENTS OF THE PACK
Each tube contains 4 grams of sterile eye ointment. The product is
sterile
until the seal on the tube is broken. The straw coloured ointment is
see-through.
MARKETING AUTHORISATION HOLDER:
Tillomed Laboratories Ltd
220 Butterfield, Great Marlings, Luton LU2 8DL, United Kingdom
MANUFACTURER

:
Tillomed Laboratories Ltd
220 Butterfield, Great Marlings, Luton LU2 8DL, United Kingdom
Montavit GmbH.
A-6060, Absam, Austria
Product Licence Number: PL 11311/0533
(1)
Only actual manufacturer will be listed on printed leaflet
This leaflet was revised in August 2018.
Simple Eye Ointment belongs to a group of medicines known as eye
lubricants (ocular lubricants).
It is used to lubricate and protect the eye in a wide range of
conditions such
as inflammation or injury to the cornea (the front surface of the eye)
or
during surgery. It is also used at night for dry and sticky eyes, and
to soften
and remove crusts from the eyelids and around the eyes in blepharitis
(inflammation of the eyelids).
PACKAGE LEAFLET: INFORMATION FOR THE USER



1
What Simple Eye Ointment is and what
it is used for


Preparatomtale

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Simple Eye Ointment
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Simple Eye Ointment contains:
Yellow Soft Paraffin
Liquid Paraffin
Wool Fat
80%w/w
10%w.w
10%w/w
3
PHARMACEUTICAL FORM
Eye ointment
Smooth, straw coloured (yellow), translucent ointment.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Simple Eye Ointment is a bland sterile preparation indicated for the
softening of
crusts in blepharitis, as a lubricant at night and to protect the
ocular surface e.g. in
keratitis, corneal conditions or during surgery.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Apply a ribbon of ointment between the lower eyelid and the eye.
As this product contains no medicament it may be used in the morning
and
night, or as required.
4.3
CONTRAINDICATIONS
Hypersensitivity to any of the ingredients.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Discard tube 28 days after first opening. Contact lenses should not be
worn during
the treatment period.
To avoid contamination during use do not allow the nozzle tip to come
in
contact with any surface.
4.5
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
None known.
4.6
FERTILITY, PREGNANCY AND LACTATION
Suitable for use in pregnancy and lactation.
4.7
EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
Application of the ointment will cause blurring of vision. Patients
should not drive or
operate machinery until their vision is clear.
4.8
UNDESIRABLE EFFECTS
Blurring of vision for 5 to 10 minutes after application.
REPORTING OF SUSPECTED ADVERSE REACTIONS
Reporting suspected adverse reactions after authorisation of the
medicinal
product is important. It allows continued monitoring of the
benefit/risk balance
of the medicinal product. Healthcare professionals are asked to report
any
suspected
adverse
reactions
via
Yellow
Card
Scheme
at:
www.mhra.gov.uk/yellowcard
4.9
OVERDOSE
Not applicable
5
PHARMACOLOGICAL PROPERTIES
5.1
PHARMACODYNAMIC PROPERTIES
Pharmacotherapeutic group: Other Ophthalmologicals.
ATC code: